These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15818142)

  • 21. Pharmacokinetic variability of extended interval tobramycin in burn patients.
    Bracco D; Landry C; Dubois MJ; Eggimann P
    Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy.
    Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G
    J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282
    [No Abstract]   [Full Text] [Related]  

  • 23. [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study].
    Le Conte P; Potel G; Clémenti E; Legras A; Villers D; Bironneau E; Cousson J; Baron D
    Presse Med; 2000 Jan; 29(2):76-8. PubMed ID: 10682031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.
    Tablan OC; Reyes MP; Rintelmann WF; Lerner AM
    J Infect Dis; 1984 Feb; 149(2):257-63. PubMed ID: 6421944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study.
    Hallal A; Cohn SM; Namias N; Habib F; Baracco G; Manning RJ; Crookes B; Schulman CI
    Surg Infect (Larchmt); 2007 Feb; 8(1):73-82. PubMed ID: 17381399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
    Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 28. Aminoglycoside and cephalosporin toxicity.
    Noone P
    J Antimicrob Chemother; 1978 Sep; 4(5):465-6. PubMed ID: 690048
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Errors associated with applying decision support by suggesting default doses for aminoglycosides.
    Eslami S; Abu-Hanna A; de Keizer NF; de Jonge E
    Drug Saf; 2006; 29(9):803-9. PubMed ID: 16944965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New schedule for tobramycin administration.
    Lawson RD; Bodey GP; Pan T; Smith TL
    Antimicrob Agents Chemother; 1980 May; 17(5):834-7. PubMed ID: 7396470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Adeboyeku D; Jones AL; Hodson ME
    J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily dosed gentamicin is more nephrotoxic than once-daily dosed tobramycin in clinically infected patients.
    van Maarseveen E; van Buul-Gast MC; Abdoellakhan R; Gelinck L; Neef C; Touw D
    J Antimicrob Chemother; 2014 Sep; 69(9):2581-3. PubMed ID: 24872345
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study.
    Kumin GD
    JAMA; 1980 Oct; 244(16):1808-10. PubMed ID: 7420681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study.
    Fong IW; Fenton RS; Bird R
    J Antimicrob Chemother; 1981 Jan; 7(1):81-8. PubMed ID: 7204294
    [No Abstract]   [Full Text] [Related]  

  • 37. Fixed exanthema from systemic tobramycin.
    García-Rubio I; Martínez-Cócera C; Robledo Echarren T; Vázquez Cortés S
    J Investig Allergol Clin Immunol; 2006; 16(4):264-5. PubMed ID: 16889285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ocular tobramycin-induced bronchospasm in an adult without asthma or atopy.
    Ting JY
    Can J Ophthalmol; 2007 Dec; 42(6):883-4. PubMed ID: 18059521
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity.
    Olsen KM; Rudis MI; Rebuck JA; Hara J; Gelmont D; Mehdian R; Nelson C; Rupp ME
    Crit Care Med; 2004 Aug; 32(8):1678-82. PubMed ID: 15286543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of nephrotoxic and ototoxic effects of tobramycin in worldwide study.
    Bendush CL; Senior SL; Wooller HO
    Med J Aust; 1977 Oct; 2(3 Pt 2 Suppl):22-6. PubMed ID: 304521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.